

March 23, 2026

SymBio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Notice Regarding Conversion of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights Issued through Third-Party Allotment, Early Redemption of the 1st Unsecured Straight Bonds, and Change in the Scheduled Timing of Expenditures of Funds Raised through the 65th to 67th Stock Acquisition Rights**

TOKYO, Japan, March 23, 2026—SymBio Pharmaceuticals Limited (TSE: 4582) (“SymBio” or the “Company”) hereby announces the status of conversions of the 7th unsecured convertible bonds with stock acquisition rights issued on April 11, 2025 through a third-party allotment to Cantor Fitzgerald Europe (the “Bonds with Stock Acquisition Rights”), as well as the status of early redemptions of the 1st unsecured straight bonds issued on August 26, 2025 to EVO FUND (the “Bonds”), during the fiscal year ending December 31, 2026 (the “current fiscal year”). The Company also announces changes in the scheduled timing of expenditures of funds raised through the 65th to 67th stock acquisition rights issued on August 12, 2025 (collectively or individually, the “Stock Acquisition Rights”). Details are as set forth below.

As disclosed in the “Summary of Financial Statements for the Fiscal Year Ended December 31, 2025 [Japanese GAAP] (Consolidated)” released on February 5, 2026, the amount of bonds scheduled to be redeemed within one year as of December 31, 2025 was ¥682,500 thousand, and the outstanding balance of convertible bonds with stock acquisition rights as of the same day was ¥1,300,000 thousand. As of today, the amount of bonds scheduled to be redeemed within one year has decreased by ¥455,000 thousand to ¥227,500 thousand, and the balance of convertible bonds with stock acquisition rights has decreased by ¥500,000 thousand to ¥800,000 thousand.

I. Conversion and/or early redemption status of the Bonds with Stock Acquisition Rights and the Bonds

1. Name of bonds	SymBio Pharmaceuticals Limited 7th Unsecured Convertible Bonds with Stock Acquisition Rights	SymBio Pharmaceuticals Limited 1st Unsecured Straight Bonds
2. Allottee	Cantor Fitzgerald Europe	EVO FUND
3. Payment date	April 11, 2025	August 26, 2025
4. Issue price	¥600,000,000	¥1,235,000,000
5. Total amount of bonds converted or redeemed prior to maturity during the current fiscal year	¥500,000,000*1	¥455,000,000*2
6. Outstanding balance of bonds as of the end of the previous fiscal year	¥600,000,000	¥682,500,000
7. Outstanding balance of bonds as of today	¥100,000,000	¥227,500,000

\*1. All bonds were converted, and none were redeemed prior to maturity.

\*2. The early redemption of the Bonds was funded in part by proceeds paid in upon the exercise of the 65th stock acquisition rights.

## II. Change in the scheduled timing of expenditures of funds raised through the Stock Acquisition Rights

In light of the status of exercises of the Stock Acquisition Rights as of today, the Company has revised the scheduled timing of expenditures of the funds raised through the Stock Acquisition Rights, as below.

At a meeting of the Board of Directors held on July 22, 2025, the Company resolved that the total amount of the Bonds would be determined by deducting, from ¥1,300,000,000, the amount equivalent to the funds paid in upon the exercise of the Stock Acquisition Rights during the period from August 13 to August 25, 2025. As disclosed in the “Notice Regarding the Completion of Payment for the 1st Unsecured Straight Bonds” dated August 26, 2025, the Company ultimately issued the Bonds in an aggregate amount of ¥1,235,000,000. Accordingly, in light of these circumstances, the Company has also revised the amount of the intended use of funds raised through the Stock Acquisition Rights.

(Revisions are underlined.)

(Before change)

Specific use of funds	Amount (millions of yen)	Scheduled timing of expenditure
1. Redemption of unsecured straight bonds	<u>1,300</u>	August 2025– <u>December 2025</u>
2. Development of brincidofovir (direct expenses)	5,442	March 2026 – March 2028
3. Development of brincidofovir (indirect expenses)	<u>1,611</u>	March 2026 – March 2028
Total	8,353	

(After change)

Specific use of funds	Amount (millions of yen) (amount allocated)	Scheduled timing of expenditure
1. Redemption of unsecured straight bonds	<u>1,235 (1,007.5)</u>	August 2025– <u>October 2026</u>
2. Development of brincidofovir (direct expenses)	5,442	March 2026–March 2028
3. Development of brincidofovir (indirect expenses)	<u>1,676</u>	March 2026 – March 2028
Total	8,353	

For details on the Bonds with Stock Acquisition Rights, please refer to the “Notice Regarding the Conclusion of Agreement to Establish a Bond Issuance Program with Stock Acquisition Rights and the Issuance of the 4th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment,” released on December 25, 2024, and the “Notice Regarding the Issuance of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment Based on the Agreement to Establish a Bond Issuance Program with Stock Acquisition Rights,” released on March 25, 2025. For details on the Bonds, please see the “Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights,” released on July 22, 2025, and the “Notice Regarding the Completion of Payment for the 1st Unsecured Straight Bonds,” released on August 26, 2025.